Saturday, September 14, 2024

TOPICS

Home Tags Benjamin Barlock

Tag: Benjamin Barlock

Slater Technology Fund to invest in Alcinous Pharmaceuticals

PROVIDENCE – The Slater Technology Fund, along with private angel investors, will invest up to $600,000 in Alcinous Pharmaceuticals, the nonprofit seed fund announced...
SLATER TECHNOLOGY FUND is investing in Alcinous Pharmaceuticals.

Slater Technology Fund to invest in Alcinous Pharmaceuticals

PROVIDENCE – The Slater Technology Fund, along with private angel investors, will invest up to $600,000 in Alcinous Pharmaceuticals, the nonprofit seed fund announced...
TEAM MEETING: From left, Brenton DeBoef, professor of chemistry at the University of Rhode Island, and Alcinous Pharmaceutical team members Nicholas DaSilva, CEO and Ph.D. student in the URI College of Pharmacy; Benjamin Barlock, chief technology officer and Ph.D. student in the URI College of Pharmacy; David Worthen, chief operations officer and URI assistant professor in the Department of Biomedical and Pharmaceutical Sciences and the Department of Chemical Engineering; and Ken Rose, chief scientific officer and Ph.D. student in the URI College of Pharmacy, discuss Alcinous’ latest research project. / PBN PHOTO/RUPERT WHITELEY

Alcinous to use $50K Innovation Voucher to create new PARP inhibitor

Five weeks prior to celebrating its first year in business, Alcinous Pharmaceuticals received a $50,000 Innovation Voucher from R.I. Commerce Corp. The microcompany had been...
INSPIRED: From left, Nicholas DaSilva, Benjamin Barlock and Kenneth Rose, Ph.D. students at the University of Rhode Island’s College of Pharmacy, discuss the drug-development company they launched, Alcinous Pharmaceuticals. / COURTESY URI/NORA LEWIS

Campus business in drug research

Fed up with the “status quo” in the pharmaceutical industry and inspired by the “endless possibilities” in drug development, current University of Rhode Island...
- Featured Event -

Latest News